All News
Jacob van Laar on difficult to treat (D2T) RA. Comorbidities, fibromyalgia, obesity contribute to this. Associated with pauci-immune synovial pathotype. A consensus definition of D2T developed and est 5-20% of RA meet this criteria #EULAR2022 @RheumNow https://t.co/MgxJIJgxYw
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2022 Difficult to treat RA (D2TRA):
Synovial pathotype shows a pauci-immune phenotype, different from other forms of RA
@RheumNow https://t.co/0osG5Bb5yb
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022 Difficult to treat RA
Which is the only independent risk factor in Netherlands study for D2TRA?
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Those #EULAR2022 vaccination bracelets are not the most discrete of things (and you can’t take them off). https://t.co/02NrLcqzT2
Francois Nantel FNantel ( View Tweet)
POS0130 from #EULAR2022 found only a 50% concordance between PsO patients with self-reported MSK pain and US findings of PsA. Remember, not all pain in PsO is PsA. @RheumNow https://t.co/CiMUa9HNgk
Dr. Rachel Tate uptoTate ( View Tweet)
🦶🏼What drives positivity of famous Squeeze test in MTPs in RA?
MRI correlation study finds:
-in early RA, association w/
*Synovitis OR 3.2 and Inter-metatarsal bursitis OR 4.8
-in pts in remission
*Sub clinical synovitis only OR 2.5
@RheumNow #EULAR2022
OP0290 https://t.co/2CNUsaesaG
Aurelie Najm AurelieRheumo ( View Tweet)
Prof van Lear defines Difficult to Treat (D2T) RA:
Failed >2 b/tsDMARD w/diff't MOA after failing csDMARD AND signs of active/progressing disease: DAS28 ESR >3.2 or CDAI>10, high ESR/CRP, imaging, Sx's causing low QoL, pred>7.5 mg/d, rapid xray progression #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Difficult to treat RA? #EULAR2022
1) Active/progressive disease, unable to taper steroids, radiographic progressive, decreased QoL
2) Failure of medications (2+ b/tsDMARD after csDMARD)
3) Physician/patient perception
- Fatigue: not part of definition
~5-20% pts
@Rheumnow https://t.co/i5sfwoF2Gs
Eric Dein ericdeinmd ( View Tweet)
When will this madness stop!? TNFi to treat OA (yet again). Adalimumab for "inflammatory" knee OA. And again it doesn't work. @RheumNow #EULAR2022 OP0229 https://t.co/htwyLTYwG4
Links:
Richard Conway RichardPAConway ( View Tweet)
#POS0787 #EULAR2022 More data to support the association of Anti-Ribosomal P ab with Depression + Cognitive Dysfunction using functional MRI in #lupus. To screen for neuropsychiatric in ab+ patients @RheumNow https://t.co/9JQDImrHAt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
✅ #EULAR2022 positive Phase 2 results for #deucravacitinib (TYK2 inhibitor) in systemic #Lupus with SRI(4) at 32W:
- DEU 3mg BID: 58.2% (p=0.0006)
- DEU 6mg BID: 49.5% (p=0.021)
- DEU 12mg QD: higher (but NS)
vs Placebo 34.4%
+ secondary endpoints.
https://t.co/QCWqW97tre
Laurent ARNAUD Lupusreference ( View Tweet)
#Cytokine #StormHour 🌀🌪️
#EULAR2022
#Great session by Dr.Peter Nigrovic🔥
❓Why sJIA/AOSD often accompanied by MAS❓⚡️
#Always wondered about this!🤔
✅Multiple mechanisms at play
✅Whats New➡️IFN gamma switch
✅mTORC1 is the NEW PIECE in the puzzle of sJIA/AOSD/MAS!🧩🧩 https://t.co/xLzCABunMb
debaditya_roy debaditya_roy ( View Tweet)
#EULAR2022 quote of the day. I was going to go to the fatigue session @eular_org but I was too tired and burnt out! @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Subcutaneous #methotrexate in #rheumatoidarthritis is safer and better tolerated with better continuation rates than oral #MTX
#eular2022 https://t.co/cjmKntsEMe
Volker Bahr VolkerBahr ( View Tweet)
#Lovely slide when deep into the maze of AOSD!🌎🔍❓
#EULAR2022
⚡️Identify level of disease activity
⚡️Systemic/Articular?
⚡️Close monitoring
⚡️Identify non-responders early!
⏲️"DAVID" Project ongoing- validation of EULAR Disease Activity Score in AOSD!
Exciting times ahead!🔥 https://t.co/fuPPj4lEhs
debaditya_roy debaditya_roy ( View Tweet)
I also wonder about the significance of Ro52. Some of the commonly observed features like gastrointestinal dysmotility are not captured. https://t.co/UPljYf65vH
Alberta Hoi alberta_hoi ( View Tweet)
#EULAR2022
How to Manage (HOT): Lupus Nephritis
Voclosporin is the new CNI
long term reno-ischemic effects need to be looked at https://t.co/8RqayemaRu
EnvisionRheumat ERheumat ( View Tweet)
#EULAR2022
WIN session
Sarcoidosis – an update for rheumatologists
Clinical Approach https://t.co/AYOEDsnDZ6
EnvisionRheumat ERheumat ( View Tweet)
#EULAR2022 COVID orals
OP0172
Swedish COVID19-Reuma registry with n=414 ARD + 61 controls
RTX n=145, ABA n=21
In MVA, use of RTX, ABA were a/w lower Ab response. We've known this about RTX; growing data for ABA as well? https://t.co/Es9bA54m8E
Rheum Cat rheum_cat ( View Tweet)
Excited to share our recent work "IPAF: What the Rheumatologist Needs to Know."
@jeffsparks @UnaMakris @DrDavidKarp @UTSW_LungLadies @UTSWRheum https://t.co/O0BsrRyHx8 https://t.co/R3lQMGFgUb
Elena Joerns EJoerns ( View Tweet)